LATS1 and neoplasm: Notably, in the study by Moroishi, T. et al. [9] demonstrating the role of the LATS1/2 mutation in suppressing immunity in cancer, their findings were based on three different murine syngeneic tumor models (B16, SCC7, and 4T1).